tuneTypical Dose
1000-4000
Amino Acid
Aspartate
L-aspartic acid
Evidence TierDWADA NOT PROHIBITED
watchEffect Window
Not established
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Aspartate is an amino acid or related metabolite involved in protein turnover and cellular signaling. It is taken to support exercise performance, recovery, or specific metabolic pathways.
Evidence is context dependent. Trials most often evaluate exercise outcomes such as fatigue, blood flow, or muscle soreness, and some show small benefits at adequate doses. Minority uses include support for wound healing, immune function, and sleep quality. Effects vary with baseline protein intake, training status, and coingested nutrients.
Metabolic amino-acid with low evidence as isolated cognitive intervention.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- No validated nootropic/performance effect
- Potential tolerability signals
Secondary Outcomes
- Minor metabolic support claims
- GI tolerability tracking
Safety
Contraindications and Interactions
Contraindications
- Severe kidney disease
- Metabolic sensitivity
- High stimulant load
Side effects
- GI upset
- Restlessness
- Headache
Interactions
- Stimulants
- Complex amino-acid blends
Avoid if
- Renal failure
- Neuropsychiatric instability
- High-dose unsupervised use
Evidence
Study-level References
aspartate-SRC-001Adjunct intervention and nutritional mix trials.
Supplementary amino-acid literature touching aspartic acid and cognitive/performance outcomes.
Population: Mixed adult populations in broad supplement settings.
Dose protocol: Aspartate within blends or low-dose monotherapy.
Key findings: No robust directional performance effect established.
Notes: Predominantly indirect evidence and weak outcomes.
Paper content
No robust directional performance effect established.
aspartate-SRC-002Clinical and product safety syntheses.
Tolerability-focused safety summaries for amino-acid interventions.
Population: Supplement and nutrition users.
Dose protocol: Variable amino-acid dosing.
Key findings: Mild adverse-effect profile at typical doses. Uncertainty at high doses.
Notes: Underpowered dedicated safety isolation.
Paper content
Mild adverse-effect profile at typical doses; uncertainty at high doses.
aspartate-SRC-003Randomized, double-blind, placebo-controlled trial.
Sourceopen_in_newGamalEl Din SF, Elnashar AM, Elkhiat Y, et al. Evaluation of in vivo supplementation of 2660 mg D-aspartic acid and 200 mg ubiquinol and 10 mg zinc on different semen parameters in idiopathic male infertility: a randomized double blind placebo controlled study. Arch Ital Urol Androl. 2025;97(2):13554. doi:10.4081/aiua.2025.13554. PMID:40248985.
Population: Adult males with idiopathic male infertility.
Dose protocol: D-aspartic acid 2660 mg plus ubiquinol 200 mg plus zinc 10 mg daily for 3 months in 75 infertile men.
Key findings: Double-blind RCT found significant improvements in progressive sperm motility and testosterone. However, effects cannot be attributed to D-aspartic acid alone due to combination design.
Notes: Combination product (D-aspartic acid plus ubiquinol plus zinc) prevents isolating the contribution of aspartate. Male fertility context only.
Paper content
This double-blind RCT tested a combination of D-aspartic acid (2660 mg), ubiquinol (200 mg), and zinc (10 mg) daily for 3 months in 75 men with idiopathic infertility. The treatment group showed significant improvement in progressive sperm motility and a highly significant increase in total testosterone compared to placebo. While the combination design prevents attribution of effects to D-aspartic acid alone, the results support a role for D-aspartate-containing regimens in male fertility support. The co-interventions (ubiquinol and zinc) are important confounders.